{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:04:32Z","timestamp":1765814672377,"version":"3.48.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>\n                    The derived neutrophil-to-lymphocyte ratio (dNLR) has been suggested as a potential prognostic biomarker for patients undergoing immune checkpoint inhibitor (ICI) therapy, particularly in advanced gastric cancer (AGC). This study aims to evaluate the prognostic value of pretreatment dNLR in AGC patients receiving ICIs. In this retrospective study, 168 AGC patients treated with ICIs at our hospital from January 2015 to December 2019 were included. Patients were grouped based on baseline dNLR levels: high (dNLR\u2005\u2265\u20053) and low (dNLR\u2005&lt;\u20053). Treatment response was evaluated using the response evaluation criteria in solid tumors version 1.1, and progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan\u2013Meier survival analysis. Statistical analyses included Cox proportional hazards regression and log-rank tests to determine the impact of dNLR on survival outcomes. A total of 168 patients with AGC were analyzed. Baseline characteristics were generally balanced between groups, with 22.6% of patients classified as high dNLR (\u22653). Treatment response did not significantly differ according to dNLR status: objective response rate was 26.2% in the low dNLR group versus 23.7% in the high dNLR group, and disease control rate was 49.2% versus 44.8%, respectively. In contrast, survival outcomes showed significant differences. Patients with low dNLR had a markedly longer median OS (23.5 vs 15.6 months; hazard ratio\u2005=\u20051.865, 95% confidence interval: 1.216\u20133.156,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and median PFS (15.6 vs 8.5 months; hazard ratio\u2005=\u20051.916, 95% confidence interval: 1.213\u20133.028,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) compared with those with high dNLR. Multivariate Cox regression adjusting for age, Eastern Cooperative Oncology Group score, metastatic burden, and treatment modality confirmed that high dNLR independently predicted poorer PFS and OS. Pretreatment dNLR is a valuable prognostic biomarker for PFS and OS in AGC patients receiving ICI therapy. Patients with lower dNLR levels may achieve more favorable outcomes, underscoring the potential of dNLR in guiding personalized treatment strategies for AGC.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046503","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:54Z","timestamp":1765814454000},"page":"e46503","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of derived neutrophil-to-lymphocyte ratio for immune checkpoint inhibitor outcomes in advanced gastric cancer"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9481-2952","authenticated-orcid":false,"given":"Yu","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, East Hospital of Shuguang Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangjun","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, East Hospital of Shuguang Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, East Hospital of Shuguang Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, East Hospital of Shuguang Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, East Hospital of Shuguang Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, East Hospital of Shuguang Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives.","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST).","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3748\/wjg.v29.i17.2515","article-title":"Novel biomarkers for early detection of gastric cancer.","volume":"29","author":"Matsuoka","year":"2023","journal-title":"World J Gastroenterol"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1007\/s12094-023-03181-x","article-title":"Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.","volume":"25","author":"Cheng","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"e002467","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer.","volume":"9","author":"Zeng","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2020-0829","article-title":"Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.","volume":"17","author":"Zeng","year":"2021","journal-title":"Future Oncol"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"818","DOI":"10.21873\/invivo.13147","article-title":"Albumin-derived neutrophil-to-lymphocyte ratio score as a marker of nivolumab treatment sensitivity in gastric cancer: a multicenter study.","volume":"37","author":"Nakazawa","year":"2023","journal-title":"In Vivo"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"1029960","DOI":"10.3389\/fonc.2022.1029960","article-title":"Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment.","volume":"12","author":"Wan","year":"2022","journal-title":"Front Oncol"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/cancers16030560","article-title":"Therapeutic immunomodulation in gastric cancer.","volume":"16","author":"Akkanapally","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.7150\/jca.62853","article-title":"When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer.","volume":"12","author":"Kim","year":"2021","journal-title":"J Cancer"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/jcm10071412","article-title":"How to best exploit immunotherapeutics in advanced gastric cancer: between biomarkers and novel cell-based approaches.","volume":"10","author":"Ghidini","year":"2021","journal-title":"J Clin Med"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer.","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"1382183","DOI":"10.3389\/fonc.2024.1382183","article-title":"Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer.","volume":"14","author":"Zeng","year":"2024","journal-title":"Front Oncol"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/imt-2022-0080","article-title":"Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.","volume":"15","author":"Wu","year":"2023","journal-title":"Immunotherapy"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.2147\/OTT.S138039","article-title":"Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer.","volume":"10","author":"Song","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"908026","DOI":"10.3389\/fonc.2022.908026","article-title":"A meta-analysis with systematic review: efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer.","volume":"12","author":"El Helali","year":"2022","journal-title":"Front Oncol"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/jgo-23-808","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis.","volume":"15","author":"Matsas","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/j.pbj.0000000000000162","article-title":"Recent insights into the use of immune checkpoint inhibitors in gastric cancer.","volume":"7","author":"Rodrigues","year":"2022","journal-title":"Porto Biomed J"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00595-021-02236-2","article-title":"Immunotherapeutic advances in gastric cancer.","volume":"51","author":"Yoneda","year":"2021","journal-title":"Surg Today"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.2147\/OTT.S152514","article-title":"Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies.","volume":"11","author":"Togasaki","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"109371","DOI":"10.1016\/j.intimp.2022.109371","article-title":"Pre-operative neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with gastric cancer.","volume":"113","author":"Han","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"e29304","DOI":"10.1097\/MD.0000000000029304","article-title":"The current management and biomarkers of immunotherapy in advanced gastric cancer.","volume":"101","author":"Chang","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2015.08.015","article-title":"Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials.","volume":"97","author":"Abdel-Rahman","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R27-20251215","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10120-023-01435-9","article-title":"Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib\/II study.","volume":"27","author":"Lee","year":"2024","journal-title":"Gastric Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:57Z","timestamp":1765814457000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":27,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046503","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}